Effects of different treatments on early cervical cancer outcomes
Effect of Different Treatments on the Prognosis of Early Cervical Cancer: A Multicenter, Prospective, Real-world Study
This study looks at how different treatments for early cervical cancer affect recovery and quality of life for patients with specific stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Southern Medical University, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04272190 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the impact of various treatment approaches on the prognosis and complications associated with early cervical cancer, specifically focusing on patients with FIGO stage IA1 with lymphovascular space invasion and IA2-IIA2. The study will collect clinical data from cervical cancer patients undergoing radical hysterectomy across 37 hospitals from June 2020 to June 2025. It will analyze factors such as preoperative treatments, surgical methods, and types of hysterectomy to determine their effects on survival rates, complication rates, quality of life, and costs.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed early-stage cervical cancer who are scheduled for radical hysterectomy or radiochemotherapy.
Not a fit: Patients with a life expectancy of less than 6 months or those with prior malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the most effective treatment strategies for early cervical cancer, potentially improving patient outcomes.
How similar studies have performed: Other studies have explored treatment outcomes in cervical cancer, but this specific multicenter observational approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed primary adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix. 2. Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), FIGO 2018 stage IA2 to IIA2. 3. Underwent radical hysterectomy or radiochemotherapy. 4. ECOG Performance Status of 0 or 1. Exclusion Criteria: 1. Life expectancy is less than 6 months 2. No prior malignancy 3. ECOG Performance Status of 2 to 5.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Chen Chunlin, PhD — Nanfang Hospital, Southern Medical University
- Study coordinator: Chen Chunlin, PhD
- Email: ccl1@smu.edu.cn
- Phone: 13725263051
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.